CTL Induction by Soluble HPV 16 E7 Antigen

Infection with human papillovamirus (HPV) type l6 is strongly associated with the development of ceother ano-genital carcinomas. In more than 90 percent of cervical carcinomas HPV DNA can be detectedcarcinoma biopsies, the most consistently retained and expressed HPV genes are two early viral oncogwill develop a vaccine that will induce CTL responses to ano-genital carcinomas expressing the HPV lA novel vaccine consisting of soluble HPV l6 E7 proteins in a proprietary adjuvant formulation (AF)for its ability to induce E7 specific CTL in mice. Typically, CTLs are induced specifically againstantigens presented as peptides by MHC class I molecules on the cell surface. Exogenous soluble antiginduce specific CTL responses. Our noninfectious, chemically-defined formulation, AF, in combinationantigens such as ovalbumin and HIV p120 is a potent inducer of CD8+, class I- restricted, antigen spsoluble recombinant HPV 16 E7 antigen in AF as an immunogen to induce CTL responses will be examinedactivity of the E7/AF vaccine in vivo tumor model studies will be investigated.